Author: 59admin_north

Northway Biotech founder Vladas Algirdas Bumelis spoke to European Biotechnology about the company’s €61m investment in a new Vilnius manufacturing center built specifically for cell therapies and personalized medicines. The story explores how the CDMO is positioning itself at the forefront of a shifting pharmaceutical model, one where entire manufacturing processes may be dedicated to a single patient, and where speed, segregation and supply‑chain consolidation become critical enablers for next‑generation therapies. With ten production lines currently undergoing qualification and manufacturing authorisation expected within six months, Northway is already onboarding development projects and preparing clients to transition into GMP as soon as approval lands.

Bumelis outlines how the facility’s design is intended to remove traditional bottlenecks in CAR‑T and gene therapy supply chains. The piece highlights Lithuania’s strategic backing, including €48m in national development bank financing, and frames the plant as a cornerstone of the country’s ambition to grow life sciences to 5% of GDP by 2030. Together, the investment, infrastructure and co‑located capabilities illustrate a broader bet: that industrial‑scale personalised medicine will move out of hospital settings and into purpose‑built CDMOs capable of running many small processes in parallel.

Read the full story here.

BriefGlance reported on a new study unveiled at ERS 2026 showing that Albus Health’s contactless, AI‑powered bedside device can reliably predict worsening asthma symptoms simply by listening for nocturnal cough. Researchers from Leiden University Medical Centre found that every five‑fold increase in nighttime cough was linked to a 1.5x higher chance of worse symptoms the next day, with the predictive window extending up to three days. With patients monitored for a median of 9.5 hours per night and near‑perfect adherence, the study highlights how passive, ambient monitoring can deliver objective, continuous data that transforms both clinical care and drug development.

The findings mark a major shift away from subjective patient reporting and toward proactive, personalised asthma management. By capturing high‑fidelity cough data without requiring patients to wear or do anything, Albus Health is helping clinicians intervene earlier, improving trial endpoints, and reducing patient burden, signalling a new era for digital biomarkers in respiratory disease.

Read the full article here.

Racura Oncology CEO Daniel Tillett and Cereno Scientific CEO Sten Sörensen spoke to David Wild for In Vivo’s deep dive into the growing movement to resurrect shelved or abandoned drugs. The story explores how both companies are mining pharma’s “graveyard” of discontinued assets — not as a last resort, but as a strategic shortcut to reach patients faster by repurposing molecules with known safety profiles and overlooked mechanisms.

Tillett describes how Racura revived bisantrene, a decades‑old anticancer drug, by uncovering its ability to stabilize G‑quadruplex DNA structures and suppress MYC, a mechanism that had been missed in earlier development. Sörensen outlines Cereno’s work repurposing a 60‑year‑old epilepsy drug for pulmonary arterial hypertension, leveraging its epigenetic effects to modify disease progression. Together, their programs illustrate a broader shift: biotech innovators are increasingly turning to abandoned compounds as fertile ground for new therapies, provided the biology is strong and the clinical rationale is clear.

Read the full story here.

Roohi Peter, senior reporter at Labiotech, spoke with leaders from across the Nordic and global biotech ecosystem at NLS Days 2026, where epigenetics, cell therapy and next‑generation oncology platforms dominated the conversation.

Among them were Sten Sörensen, CEO of Cereno Scientific, who outlined why the company is pushing HDAC inhibition to the forefront of cardiopulmonary innovation, and CuraCell Oncology, the Swedish cell‑therapy developer advancing next‑generation TIL therapies for solid tumours. Together, they reflected a meeting shaped by scientific depth, investor appetite and a clear shift toward mechanisms capable of modifying disease biology rather than simply managing symptoms.

Sörensen described how Cereno’s repurposed HDAC inhibitor is now showing promise in pulmonary arterial hypertension through epigenetic modulation. CuraCell, meanwhile, highlighted progress on its CytoPLY™ platform and its ambition to make personalised TIL therapies faster, more potent and scalable for high‑prevalence cancers. Both companies emphasised the importance of collaboration as they move toward pivotal clinical milestones.

To read how Cereno Scientific, CuraCell and other innovators are shaping the Nordic biotech landscape, access the full article here.

Millie Nelson, senior editor for Partnering and Investment at BioXconomy, sat down with HaemaLogiX CEO Chris Baldwin to unpack the Australian biotech’s transition from private promise to public potential as it prepares for an IPO. Baldwin reflects on the unexpected momentum behind the company’s precision immunotherapy pipeline, built around the novel KMA and LMA antigens, and why market transparency, investor accountability and clinical discipline are central to HaemaLogiX’s strategy as it moves toward Phase II inflection points.

Nelson’s piece situates HaemaLogiX within a wider wave of next‑generation oncology innovation, highlighting how companies like CuraCell are also redefining the path to market with platforms designed to deliver more targeted, scalable and immune‑preserving cancer therapies. Together, these emerging players illustrate a shift in how early‑stage biotechs are approaching public markets: not with hype, but with differentiated science, clear clinical rationale and a focus on mechanisms that can meaningfully change patient outcomes.

To read the full story on HaemaLogiX’s journey — and the market forces shaping its next chapter — access the complete article here.

Foventa Therapeutics CEO Olav Hellebø spoke to Business Weekly about the company’s refreshed identity and its ambitions as it prepares for a Series A raise. The story explores how the Cambridge biotech (formerly Exonate) has rebranded to reflect its evolution from a discovery‑stage organisation into a clinical‑stage company advancing FOV407, a first‑in‑class eye‑drop treatment for non‑proliferative diabetic retinopathy. With new leadership including Chief Medical Officer Dr Zaiba Malik and Chief Financial Officer Julia Jones, Foventa is positioning itself to scale its SRPK1 inhibitor platform and accelerate development of a therapy designed to intervene earlier in diabetic eye disease.

Hellebø outlines how FOV407 has progressed through Phase Ib/IIa studies and recently secured FDA Type C meeting validation for its Phase IIb design, marking a significant milestone as the company moves toward its next stage of growth. The rebrand signals a sharpened mission: to deliver a convenient, non‑invasive treatment option for millions of patients at risk of vision loss. Together, the leadership changes, clinical momentum and Series A ambitions illustrate a company entering a new chapter with a clear scientific rationale and a strong commercial trajectory.

Read the full story here.

Drug Discovery World's Diana Turner interviewed with Dr Peter Smith, Executive Chair of Racura Oncology, following the company’s AU$34.3 million raise to advance RC220 across AML, EGFR‑mutant NSCLC and anthracycline cardioprotection.

Smith explains how Racura revived (E,E)-bisantrene (once abandoned due to solubility issues) after discovering it silences MYC by stabilising the G‑quadruplex in the MYC promoter, offering a way to tackle treatment resistance in cancers where MYC is heavily upregulated. The discussion covers Racura’s reformulation breakthrough, its Phase III plans in AML, the HARNESS‑1 trial aiming to delay osimertinib resistance, and how MYC suppression could unlock broader precision‑oncology combinations.

Read the full article here.

Drug Target Review explores why researchers at Racura Oncology are taking a fresh look at bisantrene, an anticancer drug first developed decades ago but later abandoned before reaching full clinical potential. The article highlights how modern molecular tools have revealed new mechanistic insights that were previously inaccessible, including evidence that bisantrene may suppress MYC, one of oncology’s most challenging targets, through interactions with G‑quadruplex DNA structures.

These findings have prompted renewed interest from biotech innovators who see value in revisiting discontinued compounds with strong biological rationale and known safety profiles. With new data emerging from preclinical studies and early clinical programmes, bisantrene is becoming a case study in how legacy molecules can be re‑evaluated and repurposed using today’s more advanced understanding of cancer biology.

Read the full story here.

MedNous recently sat down with the scientific and clinical leads at One‑carbon Therapeutics to explore how renewed attention on one‑carbon metabolism is reshaping the therapeutic landscape for hard‑to‑treat solid tumours. The feature traces the company’s journey from fundamental metabolic biology to a first‑in‑human programme, detailing how dysregulated folate flux, formate overflow and MTHFD1/2 activity create exploitable vulnerabilities in cancer cells — vulnerabilities that One‑carbon is now targeting with its first‑in‑class dual inhibitor, TH9619.

The article highlights how TH9619’s folate‑trapping mechanism selectively induces nucleotide shortage and DNA damage in tumour cells while sparing normal tissue, and how the ongoing ODIN Phase 1/2 study is designed to translate this biology into clinical impact for patients with advanced refractory cancers. With European sites actively enrolling and mechanistic data continuing to build, One‑carbon outlines why one‑carbon metabolism may represent one of the most promising new frontiers in precision oncology.

To read the full analysis of the science, strategy and clinical path ahead, access the complete MedNous article.

Albus Health’s CEO, Mikesh Udani, explains to Diana Andrade of Clinical Trial Vanguard, how the company’s passive, contactless bedside device is reshaping what clinical trials can measure at home by prioritizing privacy from the outset. The system captures sleep, respiratory metrics, cough and other symptoms without wearables or patient effort, enabling long‑term, clinically accurate monitoring that was previously only possible in sleep labs—crucial for paediatrics, rare diseases, oncology and chronic conditions where nighttime symptoms signal deterioration or treatment response.

Udani emphasises that privacy‑by‑design is both an ethical foundation and a commercial differentiator: Albus collects only anonymised symptom data, meets stringent global regulatory standards, and consistently earns high patient trust. This combination of passive monitoring, rigorous data protection and patient‑centred design is allowing pharma sponsors to run more inclusive, lower‑burden, higher‑quality trials across more than 40 countries.

Read the full article here.